Literature DB >> 10650805

Antiproliferative activity of interferon gamma in superficial bladder cancer.

N E Stavropoulos1, E Ioachim, L Pappa, K Hastazeris, N J Agnantis.   

Abstract

BACKGROUND: Although the antiproliferative activity of interferon gamma has been reported in various tumours, this has not been studied in bladder cancer. Proliferative cell nuclear antigen and Ki67 growth fractions were estimated in this study in superficial bladder cancer, as a measure of the antiproliferative effect of interferon gamma.
MATERIALS AND METHODS: Superficial bladder cancer samples before and after four weekly intravesical instillations of 0.7 mg IFN gamma were studied immunohistochemically for proliferative cell nuclear (PCNA) and Ki67 antigens in 25 evaluable patients.
RESULTS: Ki67 growth fraction decreased from median 5% preoperatively to 1% postoperatively (p = 0.0015) and proliferating cell nuclear antigen from 20% to 5% respectively (p = 0.0001). Net reductions of both indices after the interferon instillations were significantly higher in T1 than in Ta tumours (p = 0.0431 for Ki67, and p = 0.0350 for PCNA).
CONCLUSIONS: The intravesical instillations of the present dose of interferon gamma have a significant cytostatic effect on superficial bladder cancer cells as this is evidenced by the significant decrease of the growth fractions measured by means of the proliferating cell nuclear and the Ki67 antigens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10650805

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

Review 1.  BCG response prediction with cytokine gene variants and bladder cancer: where we are?

Authors:  Dinesh Kumar Ahirwar; Parmeet Kaur Manchanda; Rama Devi Mittal; Hemant K Bid
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-20       Impact factor: 4.553

2.  Gene Variants in Predicting BCG Response to Urinary Bladder Cancer.

Authors:  Rama Devi Mittal
Journal:  Indian J Clin Biochem       Date:  2012-02-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.